Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
SciSparc Ltd. - Ordinary Shares
(NQ:
SPRC
)
1.130
-0.030 (-2.59%)
Streaming Delayed Price
Updated: 3:59 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about SciSparc Ltd. - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
Next >
SciSparc To Acquire One Of Top Sellers Of Food Supplements, Cosmetics And Hemp-Based Products On Amazon
September 14, 2022
SciSparc Ltd. (NASDAQ: SPRC) signed a definitive agreement with Merhavit M.R.M Holding and Management Ltd (“M.R.M”), to acquire its rights to purchase, Wellution, an Amazon.com (NASDAQ:
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
September 02, 2022
On Friday, 122 stocks hit new 52-week lows.
Via
Benzinga
Additional Positive Results Revealed In Cocaine Addiction Treatment Through SciSparc-Clearmind Collaboration
August 25, 2022
SciSparc Ltd. (NASDAQ: SPRC) recently announced additional positive pre-clinical results of its Psychedelic-based Pharma Collaboration for treatment for cocaine addiction using MEAI, a novel...
Via
Benzinga
SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.
August 25, 2022
Results indicate significant decrease in cocaine craving in a sub-group that received the treatment
Via
Benzinga
SciSparc Issued Israeli Patent For Its Core Technology For Treating Central Nervous Systems Disorders
August 12, 2022
Patent extends protection for SciSparc’s novel compounds and methods already granted in the U.S., Australia and Japan
Via
Benzinga
SciSparc Successfully Completed The Development Of Its Proprietary Drug Candidate SCI-110 For Its Upcoming Phase IIb Study In Tourette Syndrome
June 29, 2022
TEL AVIV, Israel, June 29, 2022 /PRNewswire/ -- SciSparc Ltd.
Via
Benzinga
SciSparc Announces Ethics Committee Approval To Conduct Its Clinical Trial In Autism Spectrum Disorder
June 23, 2022
The Soroka University Ethics Committee Approval Received to Conduct a Clinical trial with SciSparc’s Proprietary SCI-210 Treatment
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
August 30, 2022
On Tuesday, 250 stocks hit new 52-week lows.
Via
Benzinga
SciSparc Reinforces Its New JV For Targeting Discovery With A Global Expert In The Field Of Mitochondrial Transport Proteins
June 15, 2022
JV Targets Potential Drugs for Cancers and Infectious Diseases
Via
Benzinga
Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday
August 25, 2022
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) shares gained 66.5% to close at $7.51 after Point72 Asset Management reported an 8.8% passive stake in the company.
Via
Benzinga
Psychedelic-Based Cocaine Addiction Treatment Study Showing Positive Results. This Is What We Know
August 24, 2022
Israeli-Canadian biotech psychedelics developer Clearmind Medicine Inc. (OTC Pink: CMNDF) together with clinical-stage cannabinoid pharma company SciSparc Ltd.
Via
Benzinga
Why Are Psychedelics Stocks Up Today?
August 24, 2022
Shares of SEEL stock are in the green after the company received a grant from the Michael J. Fox Foundation to advance its SLS-004 candidate.
Via
InvestorPlace
S&P 500 Edges Higher; Nordstrom Shares Plummet
August 24, 2022
U.S. stocks traded slightly higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Wednesday.
Via
Benzinga
Dow Rises Over 100 Points; US Crude Oil Inventories Decline Higher Than Expected
August 24, 2022
U.S. stocks extended gains midway through trading, with the Dow Jones gaining more than 100 points on Wednesday.
Via
Benzinga
Why SciSparc Stock Is Skyrocketing Today
August 24, 2022
SciSparc Ltd (NASDAQ: SPRC) shares are soaring Wednesday after the company announced additional pre-clinical results of its psychedelic-based pharma collaboration for treatment of cocaine addiction...
Via
Benzinga
Why Citi Trends Is Trading Lower By 17%, Here Are 47 Stocks Moving In Wednesday's Mid-Day Session
August 24, 2022
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 77% to $2.35. Bright Minds priced overnight marketed offering of 2.858 million units at $1.40 per unit.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
August 17, 2022
We've got the news behind the biggest pre-market stock movers for Wednesday morning that traders need to know about this morning!
Via
InvestorPlace
Why Hill International Shares Are Trading Higher By 58%: Here Are 25 Stocks Moving Premarket
August 17, 2022
Gainers Hill International, Inc. (NYSE: HIL) shares rose 58.1% to $2.75 in pre-market trading after the company agreed to be acquired by Global Infrastructure Solutions Inc. for $2.85 per share.
Via
Benzinga
This Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday
August 16, 2022
Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 115.7% to close at $17.73 on volatility following the company's IPO earlier this month.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
August 15, 2022
On Monday, 31 companies hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
August 12, 2022
On Friday, 39 companies reached new 52-week lows.
Via
Benzinga
These Biotechs Are Reportedly Reinvigorating Alzheimer's Disease Research With Novel Drugs That Push Beyond Traditional Approaches
July 20, 2022
More than 55 million people worldwide have dementia — with about 60% to 70% of those cases resulting from Alzheimer’s disease — and that number is expected to triple by 2050.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
July 28, 2022
On Thursday, 108 companies set new 52-week lows.
Via
Benzinga
SciSparc Closer To Phase II-B Trial Of Its Dronabinol Based Drug For The Treatment Of Tourette Syndrome
July 08, 2022
SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, has started the process of...
Via
Benzinga
SciSparc Announces Buyback Equal To 12% Of Float
July 07, 2022
SciSparc Ltd. (NASDAQ: SPRC) recently announced that its board of directors authorized the company to take actions to implement a $1 million buyback program for the Company’s ordinary shares, no par...
Via
Benzinga
SciSparc Completes Development Of Its Proprietary Drug Candidate SCI-110 To Treat Tourette Syndrome
June 30, 2022
SciSparc Ltd. (NASDAQ: SPRC) announced that it has successfully completed the development of its top-tier drug candidate SCI-110 to be used in its upcoming multinational, multicenter, Phase IIb study...
Via
Benzinga
SciSparc Awaiting Approval For Phase IIb Study Of Its Dronabinol Based Drug For Treatment Of Tourette Syndrome
June 29, 2022
SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, has successfully completed...
Via
Benzinga
SciSparc And Polyrizon Report Joining Forces To Develop A Non-Opioid Pain Relief Nasal Spray
June 28, 2022
The opioid crisis has raised public awareness about the dire state of pain-management options for the estimated 50 million Americans with chronic pain.
Via
Benzinga
SciSparc Receives Ethics Committee Approval To Conduct Clinical Trial In ASD With Proprietary SCI-210 Treatment
June 24, 2022
SciSparc Ltd.
Via
Benzinga
93 Biggest Movers From Yesterday
June 14, 2022
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.